Microglia Density and Its Association With Disease Duration, Severity, and Orexin Levels in Patients With Narcolepsy Type 1
Lucie Barateau, Anis Krache, Alexandre Da Costa, Michel Lecendreux, Rachel Debs, Sofiène Chenini, Nicolas Arlicot, Patrick Vourc’h, Elisa Evangelista, Mathieu Alonso, Anne‐Sophie Salabert, Stein Silva, Séverine Béziat, Isabelle Jaussent, Denis Mariano‐Goulart, Pierre Payoux, Yves Dauvilliers
Abstract
BACKGROUND AND OBJECTIVES: F]DPA-714 PET and to study in NT1 the relationships between microglia density in the hypothalamus and in other regions of interest (ROIs) with disease duration, severity, and ORX levels. METHODS: F]DPA-714 PET imaging using a radiolabeled ligand specific to the 18 kDa translocator protein (TSPO). TSPO genotyping determined receptor affinity. Images were processed on peripheral module interface using standard uptake value (SUV) on ROIs: hypothalamus, thalamus, frontal area, cerebellum, and the whole brain. SUV ratios (SUVr) were calculated by normalizing SUV with cerebellum uptake. RESULTS: = 0.05). In NT1, no association was found between SUVr in different ROIs and age, disease duration, severity, or ORX levels. DISCUSSION: We found no evidence of in vivo increased microglia density in NT1 compared with controls, even close to disease onset, and even unexpectedly a decrease in the whole brain of these patients. These findings do not support the presence of neuroinflammation in the destruction process of ORX neurons. TRIAL REGISTRATION INFORMATION: ClinicalTrials.org NCT03754348.